Special Issue

Novel Vaccine Designs to Enhance the Engagement of Innate and Adaptive Immunity

Message from the Guest Editors

Vaccination remains one of the most effective ways to prevent diseases. It has greatly reduced or eliminated numerous infectious conditions that previously caused significant morbidity and mortality. Antigen-presenting cells have a critical role in vaccine-induced immune activation. Antibody-modulated immunity can block pathogen infection of host cells, while cellular - based immunity can recognize and kill virus-infected cells. This special issue seeks insights into novel strategies to enhance vaccination-induced immunity. The topics include but are not limited to novel delivery tools to enhance antigen presentation, nucleic acid/protein engineering for immune enhancement, targeted delivery, novel adjuvants, strategies for genetically modified live vaccines and the immune related activities engaged in such approaches. We welcome original articles, perspectives, and reviews on vaccine development against infectious diseases affecting humans and animals.

Guest Editors

Prof. Dr. Martin H. Bluth

1. Blood Transfusion and Donor Services, Maimonides Medical Center, Brooklyn, NY, USA
2. Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA

Dr. Fangfeng Yuan

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Building 76-243, Cambridge, MA 02139-4307, USA

Deadline for manuscript submissions

30 April 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/206541

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI